Home | Symbol Index | About |

Aradigm Corp (ARDM)

Aradigm Corp is related to 386 other symbols. To date we've encountered 54 releases involving Aradigm Corp.

Last Price: 1.00 (0.00) - 1/19/2007, 4:58pm

Open: N/A
High: N/A
Low: N/A

Aradigm Corp Options

Aradigm Corp "Business Partners"

Aradigm Corp Press Releases

Aradigm Corp News

Aradigm Corp Contact

Aradigm Corp Related (via TRYNT)

Aradigm Corp "Business Partners"

A "business partner" is defined as a third party company that has co-released at least one press release with Aradigm Corp.

Aradigm Corp Press Releases

Aradigm Corporation: Aradigm to Request Hearing Regarding Its Continued Listing on Nasdaq Capital Markets (Trackbacks) (Backlinks), Tue, 24 Oct 2006 14:31:00 PDT
HAYWARD, CA (MARKET WIRE) Aradigm Corporation (NASDAQ: ARDM) has requested a hearing before a NASDAQ Listing Qualifications Panel to discuss its continued listing on the NASDAQ Capital Market. This hearing is being requested as a result of preliminary financial results, which indicate that for the third quarter ended September 30, 2006, the company's shareholder equity may be below the minimum requirements of $2.5 million set forth by
Aradigm Corporation: Aradigm Files Registration Statement for Offering of Common Stock (Trackbacks) (Backlinks), Tue, 24 Oct 2006 8:49:00 PDT
HAYWARD, CA (MARKET WIRE) Aradigm Corporation (NASDAQ: ARDM) announced today that it has filed a preliminary registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed public offering of up to twenty-three million shares (including an over-allotment option of up to three million shares) of its common stock. All of the shares in the proposed offering are being sold by the company.
Aradigm: Aradigm and Novo Nordisk Execute Further Restructuring of Partnership (Trackbacks) (Backlinks), Wed, 5 Jul 2006 5:00:00 PDT
HAYWARD, CA (MARKET WIRE) Aradigm Corporation (NASDAQ: ARDM) today announced the execution of an agreement further developing the strategic partnership with Novo Nordisk. The agreement is designed to strengthen Novo Nordisk's patent position within the area of inhaled insulin as related products progress towards commercialization and has resulted in a non-dilutive cash infusion to Aradigm of $27.5 million. The Novo Nordisk
Aradigm: Aradigm Granted Hearing on Nasdaq Delisting Determination (Trackbacks) (Backlinks), Thu, 29 Jun 2006 13:00:00 PDT
HAYWARD, CA (MARKET WIRE) Aradigm Corporation (NASDAQ: ARDM) today announced that it has been granted its request for an oral hearing to appeal the Nasdaq Staff Determination to delist the Company's securities as a result of the Company's failure to comply with Nasdaq's continued listing requirements. Nasdaq has stayed the delisting of Aradigm's common stock from the Nasdaq Capital Market pending the hearing. The oral hearing is
Aradigm: Aradigm Announces Receipt of Nasdaq Staff Determination Letter; Company to Request Hearing (Trackbacks) (Backlinks), Fri, 23 Jun 2006 5:00:00 PDT
HAYWARD, CA (MARKET WIRE) Aradigm Corporation (NASDAQ: ARDM) today announced that it has received a staff determination letter from the Nasdaq Stock Market Inc. (Nasdaq) stating that the Company's common stock is subject to delisting from the Nasdaq Capital Market for not meeting specific listing criteria. The Company has the right to a hearing and will be submitting a request to the Nasdaq Listing Qualifications Panel on this
Aradigm: Aradigm Provides Further Comments on Restructuring and Cash Used in Operations (Trackbacks) (Backlinks), Wed, 17 May 2006 5:00:00 PDT
HAYWARD, CA (MARKET WIRE) Aradigm Corporation (NASDAQ: ARDM) today is providing further comments on points made in the company's recent financial press release and corresponding conference call.
Aradigm: Aradigm Reports First Quarter 2006 Financial Results and Corporate Restructuring (Trackbacks) (Backlinks), Mon, 15 May 2006 13:00:00 PDT
HAYWARD, CA (MARKET WIRE) Aradigm Corporation (NASDAQ: ARDM) today announced financial results for the first quarter of 2006 ended March 31, 2006 and a corporate restructuring.
Aradigm: Aradigm Receives FDA Orphan Drug Designation of Liposomal Ciprofloxacin for Cystic Fibrosis (Trackbacks) (Backlinks), Tue, 9 May 2006 5:00:00 PDT
HAYWARD, CA (MARKET WIRE) Aradigm Corporation (NASDAQ: ARDM) today announced it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for a proprietary liposomal formulation of ciprofloxacin for the management of cystic fibrosis.
Aradigm: Aradigm Announces Approval of Application to Transfer Stock Listing to Nasdaq Capital Markets (Trackbacks) (Backlinks), Mon, 1 May 2006 13:00:00 PDT
HAYWARD, CA (MARKET WIRE) Aradigm Corporation (NASDAQ: ARDM) today announced that The Nasdaq Stock Market has approved its application to transfer the listing of its common stock to the Nasdaq Capital Market. The transfer is expected to be effective at the open of business on Tuesday May 2, 2006. Aradigm's common stock will continue to trade under the symbol "ARDM" after the transfer is completed.
Aradigm: Aradigm Announces Update by Novo Nordisk on AERx Inhaled Insulin Phase 3 Clinical Program (Trackbacks) (Backlinks), Fri, 28 Apr 2006 6:15:00 PDT
HAYWARD, CA (MARKET WIRE) Aradigm Corporation (NASDAQ: ARDM) today reported that its partner, Novo Nordisk, has provided additional details concerning the resumption of Phase 3 clinical trials of the AERx(R) insulin Diabetes Management System (iDMS).

Aradigm Corp News

We have not detected any news yet.

Aradigm Corp Contact

Contact:
Christopher Keenan
Aradigm
(510) 265-9370

TRYNT Related

What is a Stock Cloud?

A Stock Cloud is a tag cloud like display of stock ticker symbols. The larger the ticker symbol the more frequent that company distributes press releases.